Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

BACKGROUND: Nab-paclitaxel plus gemcitabine (AG) has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone. AIM: To examine the feasibility and safety of AG adjuvant chemotherapy of resectable PDA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Clin Cases
Main Authors: Yin, Zhu-Zeng, Zhao, Zhi-Ming, Tang, Wen-Bo, Jiang, Nan, Zhang, Ke-Di, Song, Yu-Yao, Wang, Yang, Li, Cheng-Gang, Gao, Yuan-Xing, Liu, Rong
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2020
Assuntos:
Retrospective Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360710/
https://ncbi.nlm.nih.gov/pubmed/32742988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i13.2778
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados